ArticleJCI insight2020
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.
Open access · goldAbstract read
In one paragraph
Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.Frontiers in immunology · 2020Trial
- A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses.Vaccines · 2025Article
- Enhancing functional antibody responses against HIV envelope V1V2 through vaccine formulations.Frontiers in immunology · 2025Article
- Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.Viruses · 2024Review
- Increased Chemokine Production is a Hallmark of Rhesus Macaque Natural Killer Cells Mediating Robust Anti-HIV Envelope-Specific Antibody-Dependent Cell-Mediated Cytotoxicity.Pathogens & immunity · 2024Article
- Article
- Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.PLoS pathogens · 2023Article
- Multivariate analysis of FcR-mediated NK cell functions identifies unique clustering among humans and rhesus macaques.Frontiers in immunology · 2023Article
- The Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles.Viruses · 2022Review
- Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals.Nature communications · 2022Review
- Induction of tier-2 neutralizing antibodies in mice with a DNA-encoded HIV envelope native like trimer.Nature communications · 2022Article
- HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development.Current HIV/AIDS reports · 2022Review
- A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque.Vaccine · 2021Article
- Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s.Frontiers in immunology · 2021Article
- Oral Vaccination Approaches for Anti-SHIV Immunity.Frontiers in immunology · 2021Article
- Article
- Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers.Microorganisms · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 8 institutions in 2 countries.
David EasterhoffDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Justin PollaraDepartment of Medicine and.
Kan LuoDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Benjamin JanusDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
Neelakshi GohainDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
LaTonya D WilliamsDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Matthew Zirui TayDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Anthony MonroeDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Kristina PeachmanDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
Misook ChoeDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
Susie MinThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Paolo LussoThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Peng ZhangThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Eden P GoNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Heather DesaireNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.
Mattia BonsignoriDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Kwan-Ki HwangDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Charles BeckDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Matina KakalisDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Robert J O'ConnellDepartment of Chemistry, University of Kansas, Lawrence, Kansas, USA.
Sandhya VasanDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
Jerome H KimDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
Nelson L MichaelDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
Jean-Louis ExclerDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
Merlin L RobbDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
Supachai Rerks-NgarmUS Army Medical Directorate, Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand.
Jaranit KaewkungwalThai Ministry of Public Health, Nonthaburi, Thailand.
Punnee PitisuttithumMahidol Bangkok School of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Sorachai NitayaphanMahidol Bangkok School of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Faruk SinangilRoyal Thai Army Component, AFRIMS, Bangkok, Thailand.
James TartagliaGlobal Solutions for Infectious Diseases, South San Francisco, California, USA.
Sanjay PhogatGlobal Solutions for Infectious Diseases, South San Francisco, California, USA.
Kevin WieheDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Kevin O SaundersDepartment of Medicine and.
David C MontefioriDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Georgia D TomarasDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
James ArthosThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Mangala RaoDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
M Gordon JoyceDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
Gilad OfekDepartment of Cell Biology and Molecular Genetics, College of Computational, Biological, and Natural Sciences, and Institute for Bioscience and Biotechnology Research, University of Maryland, College Park, Rockville, Maryland, USA.
Guido FerrariDepartment of Medicine and.
Barton F HaynesDuke Human Vaccine Institute, Duke University, Durham, North Carolina, USA.
Duke University · USHenry M. Jackson Foundation · USUniversity of Maryland, College Park · USUniversity of Kansas · USArmed Forces Research Institute of Medical Science · THMahidol University · THMinistry of Public Health · THSanofi (United States) · US
Funding
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5MUser Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI Nozomi Ando, J Christopher Fromme · 2018 to 2026
$34.2MPhysical Resources CoreP01AI120756 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2016 to 2020
$17.1MStructure-Function Studies of the HIV-1 Envelope Glycoproteins and Development of VLP-forming vaccine strategies for HIV-1ZIAAI001197 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LUSSO, PAOLO · 2014 to 2025
$16.8MRole of IL-7 in Immune Defense against HIV-1 and Other Infectious PathogensZIAAI000976 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LUSSO, PAOLO · 2009 to 2025
$9.1MHIV-1 vaccine-elicited antibodies target envelope glycansR01AI120801 · NIAID · DUKE UNIVERSITY · PI SAUNDERS, KEVIN O · 2015 to 2024
$7.5MBasic Immunology Training ProgramT32AI052077 · NIAID · DUKE UNIVERSITY · PI KRANGEL, MICHAEL S · 2002 to 2024
$4.2MGenerating Native Env Glycosylation in HIV Vaccine CandidatesR01AI125093 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI DESAIRE, HEATHER R · 2016 to 2019
$2.7MPixel Array Detector for Macromolecular CrystallographyS10OD021527 · OD · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2016 to 2016
$2.0MCombined Hepatitis B and HIV-1 envelope vaccination to augment T cell help via linked recognition of unrelated antigensK01OD024877 · OD · DUKE UNIVERSITY · PI POLLARA, JUSTIN JOSEPH · 2017 to 2019
$1.0MNIAID NIH HHS P01 AI120756NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI120801NIAID NIH HHS R01 AI125093NIAID NIH HHS T32 AI052077NIGMS NIH HHS P30 GM124165NIH HHS K01 OD024877NIH HHS S10 OD021527
Abstract
In the RV144 HIV-1 phase III trial, vaccine efficacy directly correlated with the magnitude of the variable region 2-specific (V2-specific) IgG antibody response, and in the presence of low plasma IgA levels, with the magnitude of plasma antibody-dependent cellular cytotoxicity. Reenrollment of RV144 vaccinees in the RV305 trial offered the opportunity to define the function, maturation, and persistence of vaccine-induced V2-specific and other mAb responses after boosting. We show that the RV144 vaccine regimen induced persistent V2 and other HIV-1 envelope-specific memory B cell clonal lineages that could be identified throughout the approximately 11-year vaccination period. Subsequent boosts increased somatic hypermutation, a critical requirement for antibody affinity maturation. Characterization of 22 vaccine-induced V2-specific mAbs with epitope specificities distinct from previously characterized RV144 V2-specific mAbs CH58 and CH59 found increased in vitro antibody-mediated effector functions. Thus, when inducing non-neutralizing antibodies, one method by which to improve HIV-1 vaccine efficacy may be through late boosting to diversify the V2-specific response to increase the breadth of antibody-mediated anti-HIV-1 effector functions.
Indexed as
AIDS VaccinesAntibodies, MonoclonalAntibody-Dependent Cell CytotoxicityClinical Trials as Topicenv Gene Products, Human Immunodeficiency VirusEpitopesHIV-1HIV AntibodiesHIV InfectionsHumansImmunization, SecondaryImmunoglobulin Variable RegionModels, MolecularMutationProtein ConformationViral VaccinesAIDS VaccinesAIDSVAXALVAC vaccineAntibodies, Monoclonalenv Gene Products, Human Immunodeficiency VirusEpitopesHIV AntibodiesImmunoglobulin Variable RegionViral VaccinesAIDS/HIVAIDS vaccine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.